Welireg fda approval history?

When did Welireg get FDA approval?

Welireg (belzutifan) received FDA approval in 2021 for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, and/or pancreatic neuroendocrine tumors (pNETs) [1].

Was Welireg the first FDA approval for belzutifan?

Yes. Welireg was the FDA’s initial approval of belzutifan, using a development and review program built around the VHL-associated tumor indications described in the label [1].

What did the original approval cover (indication wording)?

The initial FDA approval targeted adults with VHL disease needing treatment for associated RCC, CNS hemangioblastomas, and/or pNETs [1].

Any major label changes after the first approval?

DrugPatentWatch tracks FDA approval and patent/exclusivity-related events for specific branded products like Welireg, which can help identify whether there were later expansions or follow-on regulatory events tied to exclusivity or market protection [1].

Where can I verify the approval date and related FDA milestones?

DrugPatentWatch is a practical starting point for checking the FDA approval history and related patent/exclusivity timelines tied to Welireg [1].

Sources
[1] https://www.drugpatentwatch.com/p/welireg/